Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41467-017-01174-3 http://scihub22266oqcxt.onion/10.1038/s41467-017-01174-3 C5666005!5666005!29093439     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Commun 2017 ; 8 (ä): ä Nephropedia Template TP {{tp|p=29093439|t=2017. Combating subclonal evolution of resistant cancer phenotypes |pdf=|usr=}}{{29093439}} gab.com Text Combating subclonal evolution of resistant cancer phenotypes JO: Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=29093439 #FOAvip Metastatic breast cancer remains challenging to treat, and most patients ultimately progress on therapy. This acquired drug resistance is largely due to drug-refractory sub-populations (subclones) within heterogeneous tumors. Here, we track the genetic and phenotypic subclonal evolution of four breast cancers through years of treatment to better understand how breast cancers become drug-resistant. Recurrently appearing post-chemotherapy mutations are rare. However, bulk and single-cell RNA sequencing reveal acquisition of malignant phenotypes after treatment, including enhanced mesenchymal and growth factor signaling, which may promote drug resistance, and decreased antigen presentation and TNF-? signaling, which may enable immune system avoidance. Some of these phenotypes pre-exist in pre-treatment subclones that become dominant after chemotherapy, indicating selection for resistance phenotypes. Post-chemotherapy cancer cells are effectively treated with drugs targeting acquired phenotypes. These findings highlight cancer?s ability to evolve phenotypically and suggest a phenotype-targeted treatment strategy that adapts to cancer as it evolves. Twit Text FOAVip Combating subclonal evolution of resistant cancer phenotypes ????Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=29093439 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29093439 #FOAvip English Wikipedia <ref>{{Cite pmid|29093439}}</ref> Combating subclonal evolution of resistant cancer phenotypes #MMPMID29093439 Brady SW; McQuerry JA; Qiao Y; Piccolo SR; Shrestha G; Jenkins DF; Layer RM; Pedersen BS; Miller RH; Esch A; Selitsky SR; Parker JS; Anderson LA; Dalley BK; Factor RE; Reddy CB; Boltax JP; Li DY; Moos PJ; Gray JW; Heiser LM; Buys SS; Cohen AL; Johnson WE; Quinlan AR; Marth G; Werner TL; Bild AH Nat Commun 2017[]; 8 (ä): ä PMID29093439show ga Metastatic breast cancer remains challenging to treat, and most patients ultimately progress on therapy. This acquired drug resistance is largely due to drug-refractory sub-populations (subclones) within heterogeneous tumors. Here, we track the genetic and phenotypic subclonal evolution of four breast cancers through years of treatment to better understand how breast cancers become drug-resistant. Recurrently appearing post-chemotherapy mutations are rare. However, bulk and single-cell RNA sequencing reveal acquisition of malignant phenotypes after treatment, including enhanced mesenchymal and growth factor signaling, which may promote drug resistance, and decreased antigen presentation and TNF-? signaling, which may enable immune system avoidance. Some of these phenotypes pre-exist in pre-treatment subclones that become dominant after chemotherapy, indicating selection for resistance phenotypes. Post-chemotherapy cancer cells are effectively treated with drugs targeting acquired phenotypes. These findings highlight cancer?s ability to evolve phenotypically and suggest a phenotype-targeted treatment strategy that adapts to cancer as it evolves. äCombating subclonal evolution of resistant cancer phenotypes (epmc).pdf DeepDyve Pubget Overpricing